We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

235 hedge funds and large institutions have $3.22B invested in Array Biopharma Inc in 2018 Q1 according to their latest regulatory filings, with 66 funds opening new positions, 83 increasing their positions, 62 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

230% more first-time investments, than exits

New positions opened: 66 | Existing positions closed: 20

46% more call options, than puts

Call options by funds: $27.3M | Put options by funds: $18.7M

34% more repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 62

26% more capital invested

Capital invested by funds: $2.56B → $3.22B (+$660M)

23% more funds holding

Funds holding: 191 → 235 (+44)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

Holders
235
Holders Change
+44
Holders Change %
+23.04%
% of All Funds
5.39%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.16%
New
66
Increased
83
Reduced
62
Closed
20
Calls
$27.3M
Puts
$18.7M
Net Calls
+$8.62M
Net Calls Change
-$12.9M

Top Buyers

1
FCM
Farallon Capital Management
California
+$49.6M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$39.5M
3
American Century Companies
American Century Companies
Missouri
+$25.4M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$22.8M
5
PAMU
Pictet Asset Management (UK)
United Kingdom
+$19.6M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$84.3M
2
BI
BVF Inc
California
-$58M
3
ACA
Avoro Capital Advisors
New York
-$56.8M
4
O
OrbiMed
New York
-$43.6M
5
Morgan Stanley
Morgan Stanley
New York
-$33.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
Zurich Cantonal Bank
201
Zurich Cantonal Bank
Switzerland
$203K +$51.3K +3,201 +35%
BCM
202
BlueCrest Capital Management
Jersey
$181K +$177K +11,072 New
BBI
203
Baxter Bros Inc
Connecticut
$166K -$64.1K -4,000 -28%
DS
204
DRW Securities
Illinois
$163K -$80.1K -5,000 -33%
LTFS
205
Ladenburg Thalmann Financial Services
Florida
$140K +$71.6K +4,470 +108%
APP
206
Avantax Planning Partners
Iowa
$103K +$101K +6,305 New
LWCFA
207
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$98K – – –
QI
208
QS Investors
New York
$75K -$94.5K -5,900 -56%
GXMC
209
Global X Management Company
New York
$60K +$14.7K +918 +34%
APA
210
American Portfolios Advisors
New York
$44.1K – – –
Bank of Montreal
211
Bank of Montreal
Ontario, Canada
$41K – – –
US Bancorp
212
US Bancorp
Minnesota
$36K +$26.7K +1,669 +341%
PMFA
213
Plante Moran Financial Advisors
Michigan
$24K +$24K +1,500 New
Simplex Trading
214
Simplex Trading
Illinois
$24K +$24.4K +1,523 New
AG
215
Advisor Group
Arizona
$19K +$16K +1,000 +571%
Daiwa Securities Group
216
Daiwa Securities Group
Japan
$18K +$17.4K +1,089 New
MYIA
217
Mount Yale Investment Advisors
Colorado
$16K +$16K +998 New
CG
218
Cutler Group
California
$15K +$14.4K +901 +3,754%
LJHT
219
Laurie J. Hall Trustee
$12K – – –
MAM
220
Meeder Asset Management
Ohio
$12K +$11.8K +737 New
AIM
221
Advantage Investment Management
Iowa
$10K +$10.1K +632 New
CPIG
222
Chicago Partners Investment Group
Illinois
$9K – – –
CAW
223
Cornerstone Advisors (Washington)
Washington
$9K – – –
SFSIG
224
San Francisco Sentry Investment Group
California
$9K +$8.41K +525 New
TA
225
Townsend & Associates
Colorado
$9K +$8.89K +555 New
7 8
9
10 11

ARRY Hedge Fund Activity: Q1 2018 in Review

235 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q1 2018, worth a combined $3.22B — up 26% from $2.56B a quarter earlier.

Buyers outnumbered sellers: 66 funds opened new ARRY positions and 20 closed out — a net gain of 46 holders — while 83 added to existing stakes and 62 trimmed.

The largest buyer was Farallon Capital Management, opening a new position worth an estimated $49.6M. The largest seller was Point72 Asset Management, cutting an estimated $84.3M.

  • 235 institutional investors held Array Biopharma Inc (ARRY) as of Q1 2018, up from 191 in Q4 2017.
  • Funds reported $3.22B of Array Biopharma Inc stock for Q1 2018, up 26% quarter-over-quarter.
  • 66 funds opened new Array Biopharma Inc positions in Q1 2018 and 20 closed out, a net change of +46 holders.
  • The largest Array Biopharma Inc buyer in Q1 2018 was Farallon Capital Management, an estimated $49.6M added.
  • The largest Array Biopharma Inc seller in Q1 2018 was Point72 Asset Management, an estimated $84.3M sold.

Based on aggregated 13F filings for Q1 2018.